293 related articles for article (PubMed ID: 33689587)
1. Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis.
Ali MF; Egan AM; Shaughnessy GF; Anderson DK; Kottom TJ; Dasari H; Van Keulen VP; Aubry MC; Yi ES; Limper AH; Peikert T; Carmona EM
Am J Respir Cell Mol Biol; 2021 Jun; 64(6):722-733. PubMed ID: 33689587
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
3. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.
Oruqaj G; Karnati S; Vijayan V; Kotarkonda LK; Boateng E; Zhang W; Ruppert C; Günther A; Shi W; Baumgart-Vogt E
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):E2048-57. PubMed ID: 25848047
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
5. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 4 activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with IPF.
Ebener S; Barnowski S; Wotzkow C; Marti TM; Lopez-Rodriguez E; Crestani B; Blank F; Schmid RA; Geiser T; Funke M
Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L42-L55. PubMed ID: 27815256
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
8. Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion.
Ahluwalia N; Grasberger PE; Mugo BM; Feghali-Bostwick C; Pardo A; Selman M; Lagares D; Tager AM
Am J Respir Cell Mol Biol; 2016 Jun; 54(6):831-42. PubMed ID: 26600305
[TBL] [Abstract][Full Text] [Related]
9. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 regulation of fibroblast activation in pulmonary fibrosis.
Sontake V; Wang Y; Kasam RK; Sinner D; Reddy GB; Naren AP; McCormack FX; White ES; Jegga AG; Madala SK
JCI Insight; 2017 Feb; 2(4):e91454. PubMed ID: 28239659
[TBL] [Abstract][Full Text] [Related]
12. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
Grimminger F; Günther A; Vancheri C
Eur Respir J; 2015 May; 45(5):1426-33. PubMed ID: 25745048
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
[TBL] [Abstract][Full Text] [Related]
15. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions.
Xu X; Dai H; Wang C
Clin Respir J; 2016 Mar; 10(2):133-41. PubMed ID: 25047066
[TBL] [Abstract][Full Text] [Related]
16. Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.
Ronan N; Bennett DM; Khan KA; McCarthy Y; Dahly D; Bourke L; Chelliah A; Cavazza A; O'Regan K; Moloney F; Plant BJ; Henry MT
Lung; 2018 Oct; 196(5):543-552. PubMed ID: 30066212
[TBL] [Abstract][Full Text] [Related]
17. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
18. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
[TBL] [Abstract][Full Text] [Related]
19. Senescence of bone marrow-derived mesenchymal stem cells from patients with idiopathic pulmonary fibrosis.
Cárdenes N; Álvarez D; Sellarés J; Peng Y; Corey C; Wecht S; Nouraie SM; Shanker S; Sembrat J; Bueno M; Shiva S; Mora AL; Rojas M
Stem Cell Res Ther; 2018 Sep; 9(1):257. PubMed ID: 30257725
[TBL] [Abstract][Full Text] [Related]
20. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
